Merck’s 11% Drop: A Few Quick Points 2-4-25

Becker Private Equity & Business Podcast - En podcast af Scott Becker

Prøv Podimo gratis! i 30 dage

Prøv Podimo gratis! i 30 dage

Et univers fyldt med hundredvis af eksklusive podcasts & lydbøger, klik her for at prøve

 Annoncering

Kategorier:

Ekonomi

In this episode, Scott Becker breaks down Merck’s 11% stock decline, discussing its strong 2024 performance, concerns over slower growth in 2025, a weak drug pipeline, and upcoming patent expirations.

Visit the podcast's native language site